Prophylaxis of Candida and Aspergillus infections with oral administration of itraconazole.
The broad-spectrum oral triazole antifungal, itraconazole, has been shown to be effective in the treatment of superficial and systemic infections with fungi including Candida albicans, C. krusei and C. glabrata, Cryptococcus, Aspergillus, Histoplasma, Blastomyces and others. Its broad spectrum of activity, high and persistent tissue levels and favourable safety profile suggest that it may be appropriate for the prevention of opportunistic fungal infections in at-risk patients. In this study, itraconazole's prophylactic efficacy was tested against experimental models of Candida and Aspergillus infection. A single dose of 1.25 mg kg-1 or 2.5 mg kg-1, given 1 h before vaginal infection with C. albicans, protected 50% of treated rats. In systemic and disseminated candidosis, prophylaxis with itraconazole reduced both folliculitis and organ Candida content in guinea pigs. Amphotericin B was also used in this study and was found to be less efficacious than itraconazole. Itraconazole prolonged survival when administered to guinea pigs before experimental induction of systemic and invasive aspergillosis. In all cases, increasing the itraconazole dosage increased its prophylactic efficacy. Therefore, as the clinical efficacy of itraconazole is accurately reflected by the results of animal models, this study shows itraconazole to be a potential prophylactic therapy for patients at risk of opportunistic fungal infection.
Van Cutsem
J
J
Janssen Research Foundation, Department of Bacteriology and Mycology, Beerse, Belgium.
D000284:Administration, Oral; D000818:Animals; D001228:Aspergillosis / Q000517:prevention & control*; D001232:Aspergillus fumigatus; D002177:Candidiasis / Q000517:prevention & control*; D002181:Candidiasis, Vulvovaginal / Q000517:prevention & control; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D017964:Itraconazole / Q000008:administration & dosage*; D008297:Male; D051381:Rats
D017964:Itraconazole